S96 An open-label extension (ext) study of lumacaftor/ivacaftor (lum/iva) therapy in patients aged 6 to 11 years with cystic fibrosis (cf) homozygous for f508del-cftr
Sign Up to like & getrecommendations! Published in 2017 at "Thorax"
DOI: 10.1136/thoraxjnl-2017-210983.102
Abstract: Objective Lumacaftor/Ivacaftor (LUM/IVA) was well tolerated and had beneficial effects on lung function, sweat chloride (SwCl), and body mass index (BMI) in a 24 week, open-label study (VX15–809–011B [011B]) in patients aged 6 to 11 years… read more here.
Keywords: week; aged years; lum; ext study ... See more keywords